Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
7,848 total articles
Biogen Inc. has entered into an agreement to acquire exclusive rights to develop and commercialize felzartamab in the Greater China region from TJ Biopharma. This acquisition consolidates global rights for felzartamab, a promising CD38-directed antibody in Phase 3 trials for multiple immune-related diseases. Biogen will make a $100 million upfront …
Palvella Therapeutics announced that results from its Phase 3 SELVA and Phase 2 TOIVA clinical trials evaluating QTORIN™ 3.9% rapamycin anhydrous gel will be presented at the ISSVA World Congress 2026. These studies demonstrated statistically significant and clinically meaningful improvements in treating microcystic lymphatic malformations and cuta…
BriaCell Therapeutics presented positive Phase 3 clinical data demonstrating preserved quality of life in heavily pretreated metastatic breast cancer patients receiving Bria-IMT combined with immune checkpoint inhibitors, alongside promising Phase 2 biomarker analyses at the 2026 AACR Annual Meeting. These findings support BriaCell's immunotherapy …
Dragonfly Energy announced a material purchase order valued at over $3 million from Stevens Transport for deployment across nearly 500 trucks throughout 2026. This order encompasses Dragonfly's full heavy-duty trucking product portfolio, including lithium-based solutions aimed at reducing engine idling, improving driver comfort, and lowering total …
New Found Gold Corp. announced a $205 million financing package consisting of a $100 million bought deal equity offering and a $105 million senior secured credit facility with EdgePoint. The funds will finance the initial capital expenditures for the Queensway Gold Project-Phase I, advancing it toward production, as well as general corporate purpos…
Clearmind Medicine Inc., a clinical-stage biotech focused on non-hallucinogenic psychedelic therapeutics, announced positive top-line safety data from its ongoing FDA-approved Phase I/IIa trial of CMND-100, a MEAI-based oral drug candidate targeting Alcohol Use Disorder (AUD). The drug met the primary safety and tolerability endpoint, showing a hig…
Gilat Satellite Networks Ltd., a leader in satellite networking technology, announced it will release its first quarter 2026 financial results on May 13, 2026. The company will host conference calls and webcasts in English and Hebrew to discuss the results and business achievements. Gilat's portfolio includes advanced satellite communication soluti…
Invivyd, Inc.'s Chairman Marc Elia is a featured speaker at the POLITICO Health Care Summit, discussing the future of viral disease prevention with emphasis on monoclonal antibodies as a next-generation approach beyond vaccines. Invivyd recently received FDA emergency use authorization for a monoclonal antibody treatment, underscoring its role in a…
Pasithea Therapeutics announced that the FDA has granted Rare Pediatric Disease Designation (RPDD) to its drug candidate PAS-004 for the treatment of Neurofibromatosis Type 1 (NF1). This designation supports the drug's potential to address this serious pediatric condition affecting approximately 115,000 individuals in the U.S. PAS-004 already holds…
Radiopharm Theranostics announced encouraging initial findings from the Phase 0/1 HEAT clinical trial evaluating 177Lu-RAD202, a first-in-class HER2-targeted radiopharmaceutical, showing meaningful tumor uptake and a favorable safety profile at the lowest 30 mCi dose. The Data Safety and Monitoring Committee has approved advancing to a higher 130 m…
U.S. Energy Corp. announced the closing of an expanded $20 million senior secured debt facility, together with proceeds from a recent equity offering, expected to complete the Phase 1 capital stack for its Big Sky Carbon Hub. The funding provides financial visibility for Phase 1 construction with commercial operations targeted for Q1 2027. The comp…
TransAlta Corporation announced key leadership changes with Mike Politeski joining as EVP and CFO and Grant Arnold as EVP and Chief Commercial Officer, effective May 2026. These appointments coincide with Joel Hunter ascending to President and CEO, following the retirement of John Kousinioris. The new executives bring extensive experience in financ…
Seres Therapeutics showcased promising Phase 1b data for its investigational live biotherapeutic SER-155 at the ESCMID Global 2026 congress. The data revealed significant and durable changes in GI microbiome composition leading to improved gastrointestinal epithelial barrier integrity in patients undergoing allogeneic hematopoietic cell transplanta…
Brady Corporation announced the acquisition of Honeywell's Productivity Solutions and Services (PSS) business in an all-cash transaction valued at approximately $1.4 billion. The acquisition expands Brady’s product portfolio into leading-edge mobility, scanning, and software solutions that serve enterprise customers in logistics, manufacturing, war…
Monte Rosa Therapeutics presented preclinical data at the AACR 2026 Annual Meeting showcasing the potential of MRT-55811, a first-in-class cyclin E1 (CCNE1)-directed molecular glue degrader. The compound demonstrated strong tumor regression in CCNE1-amplified models of ovarian, breast, and gastric cancers with superior selectivity and reduced off-t…
NRx Pharmaceuticals welcomes President Trump's Executive Order aimed at accelerating the development and approval of psychedelic medications for treating serious mental illnesses such as depression, PTSD, and suicidality. The company’s drug candidate NRX-100 has received FDA Fast Track designation and anticipates submitting a New Drug Application w…
Kustom Entertainment, Inc. declared a 1-for-5 reverse stock split of its common stock effective April 22, 2026, to raise its share price above Nasdaq's $1.00 minimum requirement. The reverse split includes a proportional reduction in authorized common shares, aiming to ensure continued listing on Nasdaq. The company specializes in advanced video re…
Pharvaris announced presentation of clinical data supporting the safety of combined use of deucrictibant immediate-release capsules and extended-release tablets for prophylactic and on-demand treatment of bradykinin-mediated angioedema, including hereditary angioedema (HAE). The data suggest adequate safety margins and potential efficacy for this c…
B2Gold Corp. announced the sale of its 70% interest in the Fingold Ventures Ltd. joint venture to Agnico Eagle Mines Limited for US$325 million in cash. Alongside this transaction, the companies have agreed to collaborate on gold mining operations in Nunavut, Canada, aiming to share expertise and improve operational efficiencies in arctic environme…
Silo Pharma highlights its lead program, SPC-15, an intranasal serotonin 4 receptor agonist targeting prophylactic treatment of PTSD, coinciding with President Trump's executive order accelerating psychedelic therapy research. SPC-15 benefits from rapid nose-to-brain delivery and a streamlined regulatory pathway, positioning the company to leverage…
Prelude Therapeutics, a clinical-stage precision oncology company, announced the pricing of an underwritten offering of approximately 18 million shares of common stock and pre-funded warrants to raise gross proceeds of about $90 million. The offering, led by RA Capital Management and participated by other healthcare-focused investors, is expected t…
KANZHUN LIMITED (BOSS Zhipin), a company listed on Nasdaq and Hong Kong stock exchanges, announced April 17th repurchases of 349,698 shares using RMB17.0 million. Year-to-date 2026, the company has invested over RMB913 million in repurchasing shares, reiterating its dedication to enhancing shareholder value.
OwlTing Group, a Nasdaq-listed global fintech company, announced a 12-month extension of lock-up agreements covering over 99% of subject shares, supported by SBI Holdings and legacy shareholders. This move aims to enhance market stability and reflects strong long-term shareholder alignment with OwlTing's strategic focus on expanding its compliant g…
Greenwich LifeSciences announced preliminary Phase III FLAMINGO-01 trial data showing statistically significant increased immune response (delayed-type hypersensitivity reactions) in non-HLA-A*02 breast cancer patients treated with GLSI-100, an immunotherapy targeting HER2-expressing cancers. Early analysis suggests a 70-80% reduction in breast can…
Tower Semiconductor announced it will release its Q1 2026 financial results on May 13, 2026, and hold a conference call to discuss the results and provide Q2 guidance. The company is a leading foundry specializing in analog semiconductor solutions, serving multiple high-growth markets with diverse technology platforms and global manufacturing facil…
